Resminostat (Kinselby) as a maintenance therapy is now clinically proven to postpone disease progression in advanced Cutaneous T-Cell Lymphoma (CTCL) which could significantly change current clinical practice.Planegg-Martinsried, Germany, 11 April 2024 – 4SC AG (4SC, FSE Prime Standard: VSC), a biotech company...
Related Keywords
Frankfurt , Brandenburg , Germany , Japan , United States , Munich , Bayern , California , Resminostat Kinselby , Rudolf Stadler , Yakult Honsha , Jason Loveridge , World Congress , Standard Of The Frankfurt Stock Exchange , University Hospital Johannes Wesling , Cutaneoust Cell Lymphoma , Cutaneous Lymphomas , Marketing Authorization , European Union , Prime Standard , Frankfurt Stock Exchange ,
comparemela.com © 2020. All Rights Reserved.